Therefore, the present study suggests that exendin-4 treatment may attenuate fat accumulation and improve glucose metabolism in liver tissues through the activation of Sirt1 signaling cascade, and further may serve as a therapeutic agent for fatty liver disease associated with metabolic diseases, such as obesity and T2DM. The gene discussed is SIRT1; the disease is obesity disorder.